Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group Inc. is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings. Cronos Group also collaborates with research partners to explore novel formats such as edibles, softgel capsules and vaporization devices, leveraging in-house extraction technologies and proprietary formulations.

Founded in 2012, Cronos Group has expanded its footprint beyond Canada through export agreements and strategic partnerships in key international markets, including Israel, Germany and Australia. In December 2018, the company entered a landmark strategic investment with Altria Group, which acquired a 45% equity stake to accelerate Cronos Group’s global expansion and product innovation efforts. Cronos Group also formed Cronos Fermentation, a joint venture with Ginkgo Bioworks, to explore fermentation-based production of rare cannabinoids at scale.

Under the leadership of CEO Michael Gorenstein and a senior management team with deep expertise in consumer packaged goods, biotechnology and regulatory affairs, Cronos Group continues to prioritize research and development, operational excellence and responsible growth. The company’s strategic focus remains on advancing scientific innovation, broadening its product portfolio and expanding its presence in regulated markets worldwide.

Key Stats

• Today's Range: $2.47 to $2.54
• 50-Day Range: $1.90 to $2.67
• 52-Week Range: $1.60 to $2.77
• Volume: 3.95 million shs
• Average Volume: 4.02 million shs
• Market Capitalization: $969.09 million
• P/E Ratio: 50.60
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 17% of companies evaluated by MarketBeat, and ranked 771st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cronos Group.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cronos Group are expected to grow in the coming year, from ($0.03) to $0.03 per share.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently increased by 8.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.40% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently increased by 8.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.52

News Sentiment

Cronos Group has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cronos Group this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for CRON on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Cronos Group is held by insiders.

Percentage Held by Institutions

Only 8.71% of the stock of Cronos Group is held by institutions.

CRON Stock Analysis - Frequently Asked Questions

How have CRON shares performed this year?

Cronos Group's stock was trading at $2.02 at the beginning of the year. Since then, CRON shares have increased by 25.2% and is now trading at $2.53.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) posted its earnings results on Thursday, August, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.08. The company earned $33.46 million during the quarter, compared to analyst estimates of $45.73 million. Cronos Group had a net margin of 14.19% and a negative trailing twelve-month return on equity of 3.78%.
Read the conference call transcript.

Who are Cronos Group's major shareholders?

Top institutional shareholders of Cronos Group include Quinn Opportunity Partners LLC (1.94%), Tidal Investments LLC (1.47%), Cannell Capital LLC (0.76%) and MMCAP International Inc. SPC (0.44%).
View institutional ownership trends.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRON
• CIK: 1656472
• Web: www.thecronosgroup.com
• Phone: (416) 504-0004
• Fax: N/A
• Employees: 450
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 50.60
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $41.08 million
• Net Margins: 14.19%
• Pretax Margin: 14.45%
• Return on Equity: -3.78%
• Return on Assets: -3.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.65
• Quick Ratio: 23.53

Sales & Book Value

• Annual Sales: $117.61 million
• Price / Sales: 8.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.95 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 383,040,000
• Free Float: 356,608,000
• Market Cap: $969.09 million
• Optionable: Optionable
• Beta: 1.13